Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting
cognition, function, and behavior. Alzheimer's disease progresses along a continuum from …

Cerebrovascular dysregulation is a hallmark of Alzheimer's disease (AD), but the changes
that occur in specific cell types have not been fully characterized. Here, we profile single …

Alzheimer's disease is a pervasive neurodegenerative disorder, the molecular complexity of
which remains poorly understood. Here, we analysed 80,660 single-nucleus transcriptomes …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

We describe a recently recognized disease entity, limbic-predominant age-related TDP-43
encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a …

Several autopsy studies recognize the locus coeruleus (LC) as the initial site of
hyperphosphorylated TAU aggregation, and as the number of LC neurons harboring TAU …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Altered microglial states affect neuroinflammation, neurodegeneration, and disease but
remain poorly understood. Here, we report 194,000 single-nucleus microglial transcriptomes …